ROSSINI, Daniela
ROSSINI, Daniela
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA. Individual patient data pooled analysis of CRICKET and CAVE trials
2023 Martini, G.; Ciardiello, D.; Famiglietti, V.; Rossini, D.; Antoniotti, C.; Troiani, T.; Napolitano, S.; Esposito, L.; Latiano, T. P.; Maiello, E.; Del , ; Re, M.; Lonardi, S.; Aprile, G.; Santini, D.; Masi, G.; Avallone, A.; Normanno, N.; Pietrantonio, F.; Pinto, C.; Ciardiello, F.; Cremolini, C.; Martinelli, E.
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.ANNALS OF ONCOLOGY, ISSN: 0923-7534
2016 Cremolini, C; Loupakis, F; Masi, G; Lonardi, S; Granetto, C; Mancini, Marialaura; Chiara, S; Moretto, R; Rossini, Daniela; Vitello, S; Allegrini, G; Tonini, G; Bergamo, F; Tomasello, G; Ronzoni, M; Buonadonna, A; Bustreo, S; Barbara, C; Boni, Maria Luisa; Falcone, A. 1. 5.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
2021 Rossini, D.; Lonardi, S.; Antoniotti, C.; Santini, D.; Tomasello, G.; Ermacora, P.; Germani, M. M.; Bergamo, F.; Ricci, V.; Caponnetto, S.; Moretto, R.; Zaniboni, A.; Pietrantonio, F.; Buonadonna, A.; Ritorto, G.; Masi, G.; Latiano, T. P.; Rapisardi, S.; Falcone, A.; Cremolini, C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA. Individual patient data pooled analysis of CRICKET and CAVE trials | 2023 | Martini, G.; Ciardiello, D.; Famiglietti, V.; Rossini, D.; Antoniotti, C.; Troiani, T.; Napolitano, S.; Esposito, L.; Latiano, T. P.; Maiello, E.; Del , ; Re, M.; Lonardi, S.; Aprile, G.; Santini, D.; Masi, G.; Avallone, A.; Normanno, N.; Pietrantonio, F.; Pinto, C.; Ciardiello, F.; Cremolini, C.; Martinelli, E. | |
| FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.ANNALS OF ONCOLOGY, ISSN: 0923-7534 | 2016 | Cremolini, C; Loupakis, F; Masi, G; Lonardi, S; Granetto, C; Mancini, Marialaura; Chiara, S; Moretto, R; Rossini, Daniela; Vitello, S; Allegrini, G; Tonini, G; Bergamo, F; Tomasello, G; Ronzoni, M; Buonadonna, A; Bustreo, S; Barbara, C; Boni, Maria Luisa; Falcone, A. 1. 5. | |
| Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO | 2021 | Rossini, D.; Lonardi, S.; Antoniotti, C.; Santini, D.; Tomasello, G.; Ermacora, P.; Germani, M. M.; Bergamo, F.; Ricci, V.; Caponnetto, S.; Moretto, R.; Zaniboni, A.; Pietrantonio, F.; Buonadonna, A.; Ritorto, G.; Masi, G.; Latiano, T. P.; Rapisardi, S.; Falcone, A.; Cremolini, C. |